Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models.

Werahera PN, Miller GJ, Torkko K, Crawford ED, Stewart JS, Deantoni EP, Miller HL, Lucia MS.

Hum Pathol. 2004 Jul;35(7):798-807.

PMID:
15257542
2.

A cross-sectional study of vasectomy, time since vasectomy and prostate cancer.

DeAntoni EP, Göktaş S, Stenner J, O'Donnell C, Crawford ED.

Prostate Cancer Prostatic Dis. 1997 Dec;1(2):73-78.

3.

Prevalence and natural history of urinary symptoms in a longitudinal national prostate cancer screening (community-based) study.

Stenner J, DeAntoni EP, O'Donnell C, Stone NN, McLeod DG, Crawford ED.

Prostate Cancer Prostatic Dis. 1998 Sep;1(5):256-261.

4.
5.

Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection.

Crawford ED, Hirano D, Werahera PN, Lucia MS, DeAntoni EP, Daneshgari F, Brawn PN, Speights VO, Stewart JS, Miller GJ.

J Urol. 1998 Apr;159(4):1260-4.

PMID:
9507848
7.

Prostate cancer clinical trials of the Southwest Oncology Group.

Crawford ED, DeAntoni EP, Hussain M, Thompson IM, Coltman CA Jr.

Oncology (Williston Park). 1997 Aug;11(8):1154-63; discussion 1163-70. Review.

8.

Age-specific reference ranges for PSA in the detection of prostate cancer.

DeAntoni EP.

Oncology (Williston Park). 1997 Apr;11(4):475-82, 485; discussion 485-6, 489. Review.

9.

Combined androgen blockade: the gold standard for metastatic prostate cancer.

McLeod DG, Crawford ED, DeAntoni EP.

Eur Urol. 1997;32 Suppl 3:70-7. Review.

PMID:
9267789
10.

Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study.

DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, Staggers F, Stone NN.

Urology. 1996 Aug;48(2):234-9.

PMID:
8753735
11.
12.

The role of prostate-specific antigen in the chemoprevention of prostate cancer.

Crawford ED, DeAntoni EP, Ross CA.

J Cell Biochem Suppl. 1996;25:149-55. Review.

PMID:
9027612
13.

Current status of combined androgen blockade: optimal therapy for advanced prostate cancer.

Crawford ED, DeAntoni EP.

J Clin Endocrinol Metab. 1995 Apr;80(4):1062-6. Review. Erratum in: J Clin Endocrinol Metab 1995 Jul;80(7):2056.

PMID:
7714067
14.

Southwest Oncology Group strategies in prostatic carcinoma.

Crawford ED, Hussain M, DeAntoni EP, Thompson IM, Eisenberger MA, Blumenstein B, Coltman CA Jr.

Semin Surg Oncol. 1995 Jan-Feb;11(1):60-4. Review.

PMID:
7754277
15.

Screening strategies: a clinical perspective.

DeAntoni EP.

Cancer Surv. 1995;23:99-114. Review.

PMID:
7542565
16.

Pretreatment of metastatic disease. Prostate cancer in the older male.

DeAntoni EP, Crawford ED.

Cancer. 1994 Oct 1;74(7 Suppl):2182-7. Review.

PMID:
8087788
17.

PSA as a screening test for prostate cancer.

Crawford ED, DeAntoni EP.

Urol Clin North Am. 1993 Nov;20(4):637-46. Review.

PMID:
7505971
18.

Chemoprevention of prostate cancer: guidelines for possible intervention strategies.

Crawford ED, Fair WR, Kelloff GJ, Lieber MM, Miller GJ, Scardíno PT, DeAntoni EP.

J Cell Biochem Suppl. 1992;16H:140-5. Review.

PMID:
1337764

Supplemental Content

Loading ...
Support Center